Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.47 |
| ▸ | GPR183 | P32249 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | EEF2K | O00418 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861666 | 0.91 | MCHR1 (0.58) | MCHR1CHRM1HTR2AGPR183CHRM4 | |
| SCHEMBL13683394 | 0.90 | MCHR1 (0.57) | MCHR1CHRM1HTR2AGPR183CHRM4 | |
| SCHEMBL3859239 | 0.84 | MCHR1 (0.98) | MCHR1CHRM1NPC1HTR2AGPR183 | |
| SCHEMBL3861187 | 0.84 | CHRM1 (0.50) | MCHR1CHRM1HTR2A | |
| SCHEMBL3867053 | 0.83 | MCHR1 (1.00) | MCHR1CHRM1HTR2AGPR183CYP2D6 | |
| SCHEMBL3866519 | 0.83 | MCHR1 (1.00) | MCHR1CHRM1HTR2AGPR183CYP2D6 | |
| SCHEMBL3860626 | 0.81 | MCHR1 (0.69) | MCHR1CHRM1NPC1HTR2ACYP2D6 | |
| SCHEMBL3875726 | 0.80 | MCHR1 (0.71) | MCHR1CHRM1NPC1HTR2A | |
| SCHEMBL3863299 | 0.80 | MCHR1 (0.74) | MCHR1CHRM1HTR2AGPR183CYP2D6 | |
| SCHEMBL3861763 | 0.79 | MCHR1 (0.76) | MCHR1CHRM1HTR2AGPR183CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | MCHR1 1/4885CHRM1 103/4885NPC1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.